PMID- 37580372 OWN - NLM STAT- MEDLINE DCOM- 20231121 LR - 20231123 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Aug 14 TI - Eschar dissolution and the immunoregulator effect of keratinase on burn wounds. PG - 13238 LID - 10.1038/s41598-023-39765-4 [doi] LID - 13238 AB - At present, enzyme debridement preparation has shown a good curative effect on eschar removal of burn wounds. Keratinase has shown great potential in enzymatic debridement because of its good fibrin-degrading ability. In this study, the debridement of keratinase was examined by using a third degree burn wound model in rats. We observed the wound, and keratinase shortened the time of eschar dissolution after debridement. Histopathology and immunofluorescence staining showed that the eschar in the keratinase group became thinner, inflammatory cell infiltration in the wound increased, the fluorescence intensity of the macrophage surface marker CD68 increased, and the CD163/CD86 ratio increased. In bone marrow-derived macrophages (BMDMs), there was no significant difference in the activity of CCK-8 in cells in the keratinase group compared with the control group. The fluorescence intensity of the keratinase group was higher than that of the control group. At 12 h, the cell scratches were obviously closed. The number of migrated Transwell cells increased. Flow cytometry and immunofluorescence analysis showed increased expression of CD206 and Arg-1 and decreased expression of CD86 and iNOS. The gene expression of the Arg-1, iNOS and IL-10 was increased, as shown by qPCR. The secretion of IL-10 was increased and TNF-alpha was decreased, as shown by ELISA. We concluded that keratinase dissolution of eschar not only has a hydrolytic effect on eschar but may also affect immune regulation to enhance the migration and phagocytosis of macrophages, promote the polarization of macrophages, and further enhance the effect of eschar dissolution. Therefore, keratinase may have good prospects for the debridement of burn wounds. CI - (c) 2023. Springer Nature Limited. FAU - Xu, Yan AU - Xu Y AD - Wuxi Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Wuxi, 214041, China. AD - Affiliated Hospital of Jiangnan University, Wuxi, 214041, China. FAU - Hu, Kai AU - Hu K AD - Nanjing University of Chinese Medicine, Nanjing, 210023, China. FAU - Liu, Chenyang AU - Liu C AD - Affiliated Hospital of Jiangnan University, Wuxi, 214041, China. FAU - Du, Pan AU - Du P AD - Jiangnan University, Wuxi, 214122, China. FAU - Zhou, Feifan AU - Zhou F AD - Medical College of Nantong University, Nantong, 226000, China. FAU - Lu, Yichi AU - Lu Y AD - Jiangnan University, Wuxi, 214122, China. FAU - Fu, Qiuyan AU - Fu Q AD - Jiangnan University, Wuxi, 214122, China. FAU - Xu, Jianmin AU - Xu J AD - Affiliated Hospital of Jiangnan University, Wuxi, 214041, China. 592220975@qq.com. FAU - Lyu, Guozhong AU - Lyu G AD - Affiliated Hospital of Jiangnan University, Wuxi, 214041, China. luguozhong@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230814 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - EC 3.4.- (keratinase) SB - IM MH - Male MH - Animals MH - Rats MH - Rats, Sprague-Dawley MH - Solubility MH - *Burns/enzymology/immunology MH - Macrophages/immunology PMC - PMC10425458 COIS- The authors declare no competing interests. EDAT- 2023/08/15 00:42 MHDA- 2023/08/16 06:43 PMCR- 2023/08/14 CRDT- 2023/08/14 23:19 PHST- 2023/02/01 00:00 [received] PHST- 2023/07/30 00:00 [accepted] PHST- 2023/08/16 06:43 [medline] PHST- 2023/08/15 00:42 [pubmed] PHST- 2023/08/14 23:19 [entrez] PHST- 2023/08/14 00:00 [pmc-release] AID - 10.1038/s41598-023-39765-4 [pii] AID - 39765 [pii] AID - 10.1038/s41598-023-39765-4 [doi] PST - epublish SO - Sci Rep. 2023 Aug 14;13(1):13238. doi: 10.1038/s41598-023-39765-4.